Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial.
Signe Møller-BisgaardKim Hørslev-PetersenLykke Midtbøll ØrnbjergBo EjbjergMerete Lund HetlandJakob Møllenbach MøllerSabrina Mai NielsenDaniel GlinatsiCecilie Lerche NordbergKristian Stengaard-PedersenOle Rintek MadsenBente JensenJan Alexander VilladsenEllen Margrethe HaugeOliver HendricksHanne M LindegaardNiels Steen KroghAnne Grethe JurikHenrik S ThomsenRobin ChristensenMikkel ØstergaardPublished in: RMD open (2024)
A 2-year combined MRI and clinical treat-to-target strategy, compared with a conventional clinical treat-to-target strategy alone, had no effect on the long-term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- magnetic resonance imaging
- juvenile idiopathic arthritis
- contrast enhanced
- randomized controlled trial
- computed tomography
- clinical trial
- study protocol
- diffusion weighted imaging
- systemic sclerosis
- ulcerative colitis
- open label